TP53 and B-cell chronic lymphocytic leukemia: To further investigate the influence of IGHV status as well as TP53 mutation on sensitivities toward drug combinations, we tested for such associations using marginal testing (t-test) for all drug–drug combinations that had at least three samples in each group (i.e., M-CLL/U-CLL or TP53wt/mut, respectively).